CN104758930A - 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 - Google Patents
一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 Download PDFInfo
- Publication number
- CN104758930A CN104758930A CN201510115729.8A CN201510115729A CN104758930A CN 104758930 A CN104758930 A CN 104758930A CN 201510115729 A CN201510115729 A CN 201510115729A CN 104758930 A CN104758930 A CN 104758930A
- Authority
- CN
- China
- Prior art keywords
- oxygenated graphene
- magnetic oxygenated
- magnetic
- gel
- polyethylene imine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 167
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 165
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000011065 in-situ storage Methods 0.000 title abstract description 11
- 229920002873 Polyethylenimine Polymers 0.000 claims abstract description 62
- 229920001661 Chitosan Polymers 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 76
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 57
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 56
- 238000003756 stirring Methods 0.000 claims description 49
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 47
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 35
- 239000012498 ultrapure water Substances 0.000 claims description 35
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 25
- 239000002244 precipitate Substances 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 24
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 229940041181 antineoplastic drug Drugs 0.000 claims description 19
- 239000012065 filter cake Substances 0.000 claims description 16
- 238000001291 vacuum drying Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 230000000259 anti-tumor effect Effects 0.000 claims description 13
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 claims description 12
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 9
- 238000005352 clarification Methods 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 230000006196 deacetylation Effects 0.000 claims description 8
- 238000003381 deacetylation reaction Methods 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 8
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 8
- 238000003760 magnetic stirring Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 229940035857 doxorubicin hydrochloride 10 mg Drugs 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000003937 drug carrier Substances 0.000 abstract description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000006482 condensation reaction Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 238000000015 thermotherapy Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000012377 drug delivery Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 4
- 229930195573 Amycin Natural products 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003578 releasing effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 101100150273 Caenorhabditis elegans srb-1 gene Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010043966 Tongue neoplasm malignant stage unspecified Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 201000005264 laryngeal carcinoma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000030940 penile carcinoma Diseases 0.000 description 2
- 201000008174 penis carcinoma Diseases 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 amine compound Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510115729.8A CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510115729.8A CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104758930A true CN104758930A (zh) | 2015-07-08 |
CN104758930B CN104758930B (zh) | 2017-09-01 |
Family
ID=53641240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510115729.8A Expired - Fee Related CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104758930B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037820A (zh) * | 2015-07-14 | 2015-11-11 | 广东海洋大学 | 一种壳聚糖低温水凝胶及其制备方法 |
CN105903077A (zh) * | 2016-04-14 | 2016-08-31 | 山东景源生物科技有限公司 | 用于促进软骨再生修复的生物基质凝胶材料的制备方法、凝胶性能测定方法及应用 |
CN106074741A (zh) * | 2016-06-15 | 2016-11-09 | 腾科宝迪(厦门)生物科技有限公司 | 一种石墨烯凝胶制剂及其制备方法和应用 |
CN106362692A (zh) * | 2016-11-07 | 2017-02-01 | 深圳市北测检测技术有限公司 | 一种磁性氧化石墨烯及其应用 |
CN107583049A (zh) * | 2017-10-30 | 2018-01-16 | 江南大学 | 一种具有光热性能的可注射性水凝胶的制备方法 |
CN107961378A (zh) * | 2017-11-22 | 2018-04-27 | 江苏大学 | 一种磁性氧化石墨烯-壳聚糖/葡聚糖复合物的制备方法及应用 |
CN107970224A (zh) * | 2017-11-23 | 2018-05-01 | 江苏大学 | 一种脂质修饰磁性氧化石墨烯复合材料的制备方法及应用 |
CN108014092A (zh) * | 2017-11-23 | 2018-05-11 | 江苏大学 | 一种磁性氧化石墨烯-鱼精蛋白/羧甲基纤维素钠复合物的制备方法及应用 |
CN109078195A (zh) * | 2018-08-30 | 2018-12-25 | 青岛大学 | 壳层含石墨烯量子点、内核含磁性纳米粒子的热敏型载药微有机凝胶及其制备方法与应用 |
CN109125724A (zh) * | 2018-09-03 | 2019-01-04 | 浙江理工大学 | 一种具有磁靶向及磁热辅助光热治疗作用的药物载体的制备方法 |
CN109364300A (zh) * | 2018-12-07 | 2019-02-22 | 昂赛国际生物科技(北京)有限公司 | 一种负载间充质干细胞的温敏水凝胶液体支架及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104323985A (zh) * | 2014-11-07 | 2015-02-04 | 郑州大学 | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 |
-
2015
- 2015-03-17 CN CN201510115729.8A patent/CN104758930B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104323985A (zh) * | 2014-11-07 | 2015-02-04 | 郑州大学 | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
FENG-HUA CHEN等: "Synthesis of a novel magnetic drug delivery system composed of doxorubicin-conjugated Fe3O4 nanoparticle cores and a PEG-functionalized porous silica shell", 《CHEMICAL COMMUNICATIONS》 * |
LIMING ZHANG等: "Enhanced Chemotherapy Effi cacy by Sequential Delivery of siRNA and Anticancer Drugs Using PEI-Grafted Graphene Oxide", 《SMALL》 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037820B (zh) * | 2015-07-14 | 2019-04-23 | 广东海洋大学 | 一种壳聚糖低温水凝胶及其制备方法 |
CN105037820A (zh) * | 2015-07-14 | 2015-11-11 | 广东海洋大学 | 一种壳聚糖低温水凝胶及其制备方法 |
CN105903077A (zh) * | 2016-04-14 | 2016-08-31 | 山东景源生物科技有限公司 | 用于促进软骨再生修复的生物基质凝胶材料的制备方法、凝胶性能测定方法及应用 |
CN105903077B (zh) * | 2016-04-14 | 2019-05-21 | 山东景源生物科技有限公司 | 用于促进软骨再生修复的生物基质凝胶材料的制备方法、凝胶性能测定方法及应用 |
CN106074741A (zh) * | 2016-06-15 | 2016-11-09 | 腾科宝迪(厦门)生物科技有限公司 | 一种石墨烯凝胶制剂及其制备方法和应用 |
CN106362692A (zh) * | 2016-11-07 | 2017-02-01 | 深圳市北测检测技术有限公司 | 一种磁性氧化石墨烯及其应用 |
CN107583049A (zh) * | 2017-10-30 | 2018-01-16 | 江南大学 | 一种具有光热性能的可注射性水凝胶的制备方法 |
CN107583049B (zh) * | 2017-10-30 | 2021-01-01 | 江南大学 | 一种具有光热性能的可注射性水凝胶的制备方法 |
CN107961378A (zh) * | 2017-11-22 | 2018-04-27 | 江苏大学 | 一种磁性氧化石墨烯-壳聚糖/葡聚糖复合物的制备方法及应用 |
CN107970224A (zh) * | 2017-11-23 | 2018-05-01 | 江苏大学 | 一种脂质修饰磁性氧化石墨烯复合材料的制备方法及应用 |
CN107970224B (zh) * | 2017-11-23 | 2020-07-31 | 江苏大学 | 一种脂质修饰磁性氧化石墨烯复合材料的制备方法及应用 |
CN108014092A (zh) * | 2017-11-23 | 2018-05-11 | 江苏大学 | 一种磁性氧化石墨烯-鱼精蛋白/羧甲基纤维素钠复合物的制备方法及应用 |
CN109078195A (zh) * | 2018-08-30 | 2018-12-25 | 青岛大学 | 壳层含石墨烯量子点、内核含磁性纳米粒子的热敏型载药微有机凝胶及其制备方法与应用 |
CN109125724A (zh) * | 2018-09-03 | 2019-01-04 | 浙江理工大学 | 一种具有磁靶向及磁热辅助光热治疗作用的药物载体的制备方法 |
CN109364300A (zh) * | 2018-12-07 | 2019-02-22 | 昂赛国际生物科技(北京)有限公司 | 一种负载间充质干细胞的温敏水凝胶液体支架及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104758930B (zh) | 2017-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104758930A (zh) | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 | |
Fang et al. | Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery | |
Ding et al. | A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy | |
Zhao et al. | Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application | |
CN104353075B (zh) | 一种水溶性磁性二氧化钛及其制备方法与应用 | |
CN103213967B (zh) | 一种磁性水溶性碳纳米管及其制备方法和应用 | |
Yang et al. | Rod-shape MSN@ MoS2 nanoplatform for FL/MSOT/CT imaging-guided photothermal and photodynamic therapy | |
CN102898542B (zh) | 一种水溶性富勒烯及其应用 | |
CN103099784B (zh) | 一种纳米药物颗粒、其制备方法及应用 | |
CN102675655B (zh) | 一种水溶性富勒烯及其制备应用方法 | |
CN103230604B (zh) | 一种磁性水溶性富勒烯及其制备方法和应用 | |
CN104758931B (zh) | 一种基于功能化氧化石墨烯温敏水凝胶的制备方法及其应用 | |
CN103768600B (zh) | 一种磁性热敏脂质体纳米金复合物、制备方法及应用 | |
Zhang et al. | pH-sensitive and bubble-generating mesoporous silica-based nanoparticles for enhanced tumor combination therapy | |
CN103183311A (zh) | 水溶性磁靶向性氧化石墨烯衍生物的制备方法及其应用 | |
CN104758948B (zh) | 基于金纳米星的多功能抗肿瘤靶向诊断治疗药物的制备方法及应用 | |
CN102898543B (zh) | 一种水溶性碳纳米管及其应用 | |
CN103007281B (zh) | 多机制***光热控释长循环药物转运***的制备方法及其应用 | |
CN105126121B (zh) | 一种靶向金银合金纳米笼的药物递送***的制备方法及应用 | |
CN104606127A (zh) | 靶向egfr的载铂类药物白蛋白纳米粒及其制备与应用 | |
Duan et al. | Advances and prospects in the treatment of pancreatic cancer | |
Tian et al. | Engineering of an endogenous hydrogen sulfide responsive smart agent for photoacoustic imaging-guided combination of photothermal therapy and chemotherapy for colon cancer | |
CN105194679A (zh) | 有抗肿瘤药物纳米层的透明质酸修饰的二氧化钛-氧化石墨烯复合材料制备方法及应用 | |
CN105056244A (zh) | 一种介孔门控型的Fe2+供体与Fe2+依赖性抗肿瘤药物共转运体系及其制备方法与应用 | |
CN103520726B (zh) | 一种隐形热敏脂质体的制备及其药物转运***在肿瘤治疗药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zhenzhong Inventor after: Zhu Xiali Inventor after: Huang Heqing Inventor after: Zhang Yingjie Inventor after: Li Zhi Inventor after: Shi Jinjin Inventor before: Zhu Xiali Inventor before: Huang Heqing Inventor before: Zhang Yingjie Inventor before: Li Zhi Inventor before: Shi Jinjin Inventor before: Zhang Zhenzhong |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Patentee after: Zhengzhou University Address before: 450001 science avenue of Zhengzhou high tech Development Zone, Zhengzhou, Henan Province, No. Patentee before: Zhengzhou University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170901 Termination date: 20180317 |